Pfizer Inc. confirmed on Thursday that it remains committed to the financial targets it previously set for 2026, even as it announced a change in its finance leadership.
The company maintained its full-year revenue projection at between $59.5 billion and $62.5 billion. In addition, Pfizer upheld its guidance for adjusted diluted earnings per share in a range of $2.80 to $3.00.
These targets were initially provided on December 16, 2025, and were reaffirmed during Pfizer's first-quarter earnings call on May 5, 2026. The company said the reaffirmation follows those earlier disclosures and keeps the same numerical ranges intact.
Pfizer also announced a scheduled change at the top of its finance organization. Chief Financial Officer Dave Denton will depart the company effective August 15 to assume a role in the consumer goods sector. The company named Cecile Guegan as interim chief financial officer, effective August 16. Guegan currently serves as senior vice president for finance in Pfizer's global biopharmaceutical business.
Pfizer stated it will undertake a search for a permanent chief financial officer and will consider candidates both from within the company and from outside. The company provided no further timeline for that search or additional details about the process.
Context and continuity
By restating the same revenue and adjusted EPS ranges supplied in December and reaffirmed in May, Pfizer signaled that its public financial targets for 2026 remain unchanged despite the impending CFO transition. The appointment of an interim finance chief ensures that the finance function will have leadership in place following Denton's departure.
What the company has disclosed
- Revenue guidance for 2026: $59.5 billion to $62.5 billion.
- Adjusted diluted earnings per share guidance: $2.80 to $3.00 for 2026.
- CFO Dave Denton will leave on August 15 to join the consumer goods sector.
- Cecile Guegan will become interim CFO on August 16; she is currently senior vice president for finance in Pfizer's global biopharmaceutical business.
- Pfizer will search both internally and externally for a permanent CFO.
Limitations
Details beyond the items listed above were not provided. The company did not disclose a timeline for selecting a permanent CFO, specifics about the search process, or additional commentary on how the transition might affect execution of the 2026 plan.